[Efficacy of recombinant human erythropoietin (rhuEPO) in treatment of anemia in patients with myelodysplastic syndrome].
This paper summarizes results of rhuEPO--treatment obtained by different authors in 27 patients with a myelodysplastic syndrome (MDS). Only 1/3 of all patients with a MDS were responsive to rhuEPO treatment, while in 2/3 of these subjects no amelioration of anaemia was noticed, even after extremely high doses of this hormone. A detailed description of a patient with MDS, which was observed by the authors, is presented. In this patient the anaemia was refractive even after very high doses of rhuEPO administered for 10 weeks.
Wiecek
A
A
Katedry i Kliniki Nefrologii Sl. AM, Katowicach.
Chudek
J
J
Nieszporek
T
T
Kokot
F
F
D000740:Anemia / Q000209:etiology / Q000628:therapy*; D004921:Erythropoietin / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009190:Myelodysplastic Syndromes / Q000150:complications*; D011994:Recombinant Proteins / Q000627:therapeutic use
D011994:Recombinant Proteins; D004921:Erythropoietin
Skuteczność ludzkiej rekombinowanej erytropoetyny (rhuEPO) w leczeniu niedokrwistości u chorych z zespołem mielodysplastycznym.